Revelation Biosciences Inc (REVB) - News Archive

Showing 9 of 9 results.

Strategic Maneuver Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split to Optimize Market Position

: Revelation Biosciences Inc. a player in the biopharmaceutical sector, has announced a significant corporate decision to implement a 1-for-16 reverse stock split, effective January 28, 2025. This strategic move comes a...

Jan 25, 2025 • Major Pharmaceutical Preparations Industry Business Update NASDAQRaises Price Target The Schall Law Firm Inc

Strategic Financial Restructuring Revelation Biosciences Implements a 1-for-16 Reverse Stock Split

In a significant development illustrating the company s commitment to enhancing shareholder value and financial positioning, Revelation Biosciences Inc. (NASDAQ: REVB) has announced a 1-for-16 reverse stock split effect...

Jan 25, 2025 • Major Pharmaceutical Preparations Industry Business Update NASDAQRaises Price Target The Schall Law Firm Inc

Revelation Biosciences Gemini IND Accepted by FDA Amidst Competitive Revenue Struggles

Revelation Biosciences, Inc. (NASDAQ: REVB), a clinical-stage life sciences company focused on leveraging trained immunity for the treatment of various diseases, recently announced a significant milestone with the accep...

Dec 2, 2024 • Major Pharmaceutical Preparations Industry Business Update NASDAQRaises Price Target The Schall Law Firm Inc

The Upward Surge of Revelation Biosciences Inc A Promising Turnaround for Investors

Investing in the stock market can be a rollercoaster ride with unpredictable outcomes. This year, Revelation Biosciences Inc has faced challenges in meeting investor expectations, trailing behind the market s performanc...

Jun 25, 2024 • Major Pharmaceutical Preparations Industry Stocks on the Move Revelation Biosciences Inc Biotechnology At Inc In

Harnessing the Power of Trained Immunity: Promising Preclinical Data on Gemini's Potential Therapeutic Benefit for Acute Kidney Injury Prevention

Revelation Biosciences Inc. is a clinical-stage life sciences company at the forefront of harnessing trained immunity for the prevention and treatment of diseases. Recently, they presented new preclinical data on the po...

Mar 13, 2024 • Major Pharmaceutical Preparations Industry Product Service News NASDAQ

Revelation Biosciences Commences First-in-Human Phase 1 Clinical Study of Gemini: Harnessing Trained Immunity for Disease Prevention and Treatment

Harnessing Trained Immunity: Revelation Biosciences Initiates First-in-Human Phase 1 Clinical Study of GeminiIn a groundbreaking move towards revolutionizing disease prevention and treatment, Revelation Biosciences Inc....

Mar 4, 2024 • Major Pharmaceutical Preparations Industry Product Service News NASDAQ

Revelation Biosciences Inc. to Present Groundbreaking Preclinical Data on Gemini for Acute Kidney Injury Prevention at Prestigious International Conference

Revelation Biosciences Inc. (NASDAQ: REVB), a leading biotech company focused on innovative treatments for critical conditions, has received a prestigious invitation to deliver an oral presentation at The 29th Internati...

Feb 13, 2024 • Major Pharmaceutical Preparations Industry Product Service News NASDAQ

Revelation Biosciences Inc. Completes $6.2 Million Public Offering, Paving the Way for Trained Immunity Research

Revelation Biosciences Inc. Successfully Completes Public Offering, Raising $6.2 Million for Advancement in Trained Immunity ResearchSAN DIEGO - Revelation Biosciences Inc. (NASDAQ: REVB), a pioneering life sciences com...

Feb 5, 2024 • Major Pharmaceutical Preparations Industry Stock Issue News NASDAQ

Revelation Biosciences Inc. Raises $6.2 Million in Public Offering Amid Leverage Ratio Concerns

Revelation Biosciences Inc. Announces Pricing of Public Offering and Addresses Leverage Ratio ConcernsSan Diego, CA - In a press release issued today, Revelation Biosciences Inc. (NASDAQ: REVB), a life sciences company...

Feb 1, 2024 • Major Pharmaceutical Preparations Industry Financing Agreement NASDAQ